Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CDX-6114 in Healthy Volunteers
NCT03797664Phase 1Completed
- Sponsor
- Codexis, Inc.
- Start
- Dec 2018
- Primary completion
- Apr 2019
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in phenylketonuria (PKU) comparing CDX-6114 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events up to 22 days. Started Dec 2018; status: completed.
02
Drugs
CDX-6114
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT03797664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797664.